From Spore to Standard: How ISO 22441 Validation Compares to ISO 11135 (EtO) and ISO 11137 (Radiation)

Validation engineers who have spent careers with ISO 11135 (ethylene oxide) or ISO 11137 (radiation) encounter ISO 22441 (vaporized hydrogen peroxide) as unfamiliar territory. The standard has a different number, the physical sterilization mechanism is different, and the process parameters are not the same as the methods they know. That unfamiliarity produces a predictable institutional friction: the validation team's comfort with the existing method becomes, in practice, an argument against evaluating the alternative.

This article resolves that friction directly. ISO 22441:2022, ISO 11135:2014 (EtO), and ISO 11137-1:2006/Amd.1:2013 (radiation) are structural siblings. They were designed by the same ISO Technical Committee (TC 198 — Sterilization of Health Care Products), organized around the same validation lifecycle framework, and calibrated to the same sterility assurance target. The method-specific differences are real and technically important. The structural framework is identical. A validation team that understands one framework can read the other without relearning the discipline.

The comparison that follows is organized around the validation lifecycle stages that are common to all three standards: biological indicator requirements, cycle development, IQ/OQ/PQ, routine monitoring, and documentation. Within each stage, the method-specific parameters are identified precisely — because those differences are what must be understood, not obscured.

Governing Standard Structure

All three standards are published under ISO Technical Committee 198, which is responsible for the international standardization of sterilization of health care products. This shared parentage is not incidental — it means the underlying logic of validation, the SAL target, the documentation architecture, and the lifecycle management requirements are consistent across methods by design.

ISO 22441:2022 is a single-document standard covering the development, validation, and routine control of VHP processes for medical devices. It was published in 2022 as the first dedicated international VHP standard and is currently at lifecycle stage 90.20 (systematic review — active and in use).

ISO 11135:2014 governs EtO sterilization of health care products. It is the controlling standard for EtO process development, validation, and routine monitoring, and it superseded the previous ISO 11135:1994 edition. It is supplemented by ISO 10993-7:2008 for EtO residual assessment and ISO/TS 11135-1 for guidance on application.

ISO 11137 governs radiation sterilization across three parts: Part 1 covers requirements for development, validation, and routine control of a sterilization process for medical devices; Part 2 covers establishing the sterilization dose; Part 3 covers guidance on dosimetric aspects. Radiation sterilization methods covered include gamma, electron beam (E-beam), and X-ray (bremsstrahlung). The multi-part structure reflects the additional complexity of dose mapping and radiation source management that has no direct equivalent in chemical sterilization methods.

All three standards share the same fundamental objective: to provide a documented basis for the claim that a sterilization process achieves a sterility assurance level (SAL) of 10⁻⁶ — a probability of no more than one non-sterile unit per one million processed units.

Biological Indicator Requirements

The biological indicator is the organism-based challenge used to demonstrate that a sterilization process achieves sufficient lethality. All three standards specify the use of characterized biological indicators with known resistance to the sterilization agent, placed at the most challenging locations in the load configuration, and used to confirm that the validated process achieves the required log reduction.

**ISO 22441 (VHP):** The specified BI organism is *Geobacillus stearothermophilus* spores — the same organism used for steam sterilization validation. D-values are established specifically for VHP exposure conditions and are distinct from steam D-values: VHP achieves sporicidal kill through oxidation of spore coat proteins, not thermal denaturation, so D-values reflect the concentration-time product required in vapor phase at defined temperature and humidity. ISO 22441 requires BIs with characterized D-values specific to VHP, minimum spore population of 10⁶ per carrier, and BI placement at worst-case locations determined by process challenge studies.

**ISO 11135 (EtO):** The specified BI organism is *Bacillus atrophaeus* (ATCC 9372) spores — a different organism than VHP or steam. *B. atrophaeus* was selected for its resistance profile to ethylene oxide specifically; its D-value for EtO (at defined concentration, temperature, and humidity) is the characterization parameter. ISO 11135 requires BIs with certified D-values, minimum population per carrier, and challenge placement at worst-case load positions determined by distribution and penetration studies. BI incubation is typically at 37°C for 7 days, with a growth/no-growth readout. EtO BI performance is more sensitive to relative humidity — the water content of the spore is a determinant of alkylation susceptibility, and cycle humidity conditioning directly governs BI response.

**ISO 11137 (Radiation):** Radiation sterilization does not use biological indicators in the same role that chemical and gas sterilization methods do. The primary lethality verification mechanism is dosimetry — physical measurement of the radiation dose absorbed by the product and load. Dosimetry systems (alanine, PMMA, radiochromic film) are calibrated and placed at minimum-dose locations within the load; dose measurements confirm that the validated minimum dose was delivered. BIs (typically *Bacillus pumilus* ATCC 27142 for gamma and E-beam) are used in dose-setting studies (Method 1, Method 2, or VDmax under ISO 11137-2) but are not the primary routine monitoring tool that they are in chemical sterilization methods. This is the most structurally significant difference between ISO 11137 and the chemical sterilization standards — the validation evidence base is dosimetric rather than biological for routine monitoring.

The practical implication of the BI differences: for teams transitioning from EtO to VHP, the BI supplier, the organism, and the incubation protocol all change. The underlying role of the BI — placed at worst-case locations, used to demonstrate lethality at the most challenging point in the load — is identical. For teams transitioning from radiation to VHP, the shift is more fundamental: moving from dosimetry-primary to BI-primary monitoring is a workflow change that affects how cycle runs are released and how nonconformances are investigated.

Cycle Development

Cycle development is the phase in which the sterilization process parameters are established, optimized, and confirmed to be capable of achieving the required SAL. All three standards require cycle development prior to formal qualification; the method-specific parameters are what differ.

**ISO 22441 (VHP):** Cycle development establishes five independent parameters: H₂O₂ concentration (typically 250–1000 ppm in the chamber), temperature (30–50°C), relative humidity (conditioning and dwell phase), exposure time (dwell duration), and aeration (catalytic decomposition to water and oxygen). The four-phase cycle structure — conditioning, desorption, sterilization/decontamination, and aeration — is specific to VHP and has no direct equivalent in EtO or radiation. The conditioning phase establishes the thermal and humidity baseline; the desorption phase drives residual moisture off surfaces to enable VHP adsorption; the sterilization phase delivers VHP at validated concentration for the validated dwell time; aeration removes residual H₂O₂ to safe levels. ISO 22441 cycle development must demonstrate sporicidal efficacy at worst-case locations within the specific chamber, load configuration, and packaging — the cycle is not transferable between chambers or configurations without revalidation.

**ISO 11135 (EtO):** EtO cycle development establishes gas concentration (typically 450–1200 mg/L), temperature (37–63°C), relative humidity (40–80%), exposure time, and aeration time and temperature. The pre-conditioning phase — in which the product reaches temperature and humidity equilibrium before gas injection — is particularly critical for EtO because humidity conditioning governs spore hydration and therefore BI susceptibility. EtO cycle development must address penetration into the product load (EtO diffuses through packaging and lumens, so cycle parameters must be shown to achieve sufficient gas concentration at interior surfaces), as well as residual testing under ISO 10993-7 for EtO and its reaction products (ethylene chlorohydrin, ethylene glycol). Aeration for EtO is a regulatory and safety requirement as well as a technical one — residue limits are defined and enforced.

**ISO 11137 (Radiation):** Cycle development for radiation sterilization is structured as dose-setting rather than parameter development. ISO 11137-2 defines three methods for establishing the sterilization dose: Method 1 (product bioburden enumeration and dose-setting from bioburden data), Method 2 (verification dose experiment for products with bioburden ≤1000 CFU/device), and VDmax (a simplified Method 2 variant for products meeting specific bioburden criteria). The established minimum dose is then confirmed by dose mapping — measuring dose distribution throughout the irradiation container at the specific irradiator geometry and product configuration. Radiation cycle development is deterministic in a way that VHP and EtO are not: if the dose mapping confirms the minimum dose is achieved at all locations in the load, the lethality argument is physical rather than microbiological. The process parameters (dose rate, irradiation time, product orientation) are set by the irradiator facility, not the device manufacturer.

The cycle development comparison reveals the most operationally significant difference between VHP and radiation: VHP cycle development requires active parametric development by the manufacturer's validation team, working with a specific chamber and a specific load configuration. Radiation dose-setting is largely delegated to the irradiation facility and the ISO 11137-2 bioburden-based method. For manufacturers accustomed to radiation, the shift to VHP requires internalizing a process development discipline that was previously externalized to the contract irradiator. For manufacturers accustomed to EtO, the cycle development workflow is structurally familiar — both are parametric processes requiring chamber-specific development.

IQ / OQ / PQ Structure

The installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) lifecycle is the common validation architecture across all three standards. The content of each phase is method-specific; the logic and sequence are identical.

**Installation Qualification** confirms that the sterilization system has been installed per the manufacturer's specifications and that the instrumentation required to control and monitor the cycle is calibrated, functioning, and documented. For VHP, IQ documents the generator performance, chamber construction and sealing, instrumentation calibration (H₂O₂ analyzers, thermocouples, humidity sensors), and utility connections. For EtO, IQ documents the sterilizer construction, gas injection system, temperature and humidity instrumentation, and aeration system. For radiation, IQ at the irradiator facility documents the radiation source, dosimetry system calibration, conveyor system, and safety interlocks. The documentation structure is equivalent; the specific items under review differ by method.

**Operational Qualification** establishes and documents the process parameter ranges within which the system operates reproducibly. For VHP, OQ maps the distribution of H₂O₂ concentration, temperature, and humidity throughout the chamber under empty-chamber and loaded conditions, and confirms that the cycle controller maintains parameters within the validated range. For EtO, OQ maps gas concentration distribution, temperature, and humidity throughout the chamber and confirms pre-conditioning system performance. For radiation, OQ maps dose distribution throughout the irradiation container at the validated irradiator geometry and confirms dosimetry system performance. In all three methods, OQ establishes the "operational envelope" — the combination of parameter ranges within which the process can be performed reproducibly.

**Performance Qualification** demonstrates that the validated cycle, as executed on the actual system with the actual product load, achieves the required SAL. For VHP and EtO, PQ uses biological indicators at worst-case locations in the product load configuration, with the required number of consecutive successful runs (typically three) per the applicable standard. For radiation, PQ uses dose mapping at production-configuration conditions to confirm that the minimum dose is achieved throughout the load. All three standards require that PQ be performed with the actual product or product simulant in the production load configuration — PQ on an empty chamber or with a surrogate load is insufficient for the performance claim.

The IQ/OQ/PQ architecture is the aspect of ISO 22441 that is most directly transferable for teams with EtO or radiation experience. The documentation deliverables — installation qualification report, operational qualification report, performance qualification report — are structurally identical. The content of each report reflects the method-specific parameters, but the document structure, the acceptance criteria format, and the review and approval logic are the same.

Residue and Safety Assessment

Residue assessment is a post-sterilization requirement for both VHP and EtO; it is not a primary concern for radiation.

**ISO 22441 (VHP):** Residue assessment is governed by ISO 21396:2022, which specifies methods for measurement of hydrogen peroxide residuals in and on VHP-sterilized devices. Acceptable residue limits are established through biocompatibility assessment per ISO 10993-17. After a fully aerated VHP cycle, hydrogen peroxide decomposes to water and oxygen — the residue profile is favorable compared to EtO, and the decomposition products have no chemical toxicity. ISO 22441 Section 5.4.5 requires residue testing as part of PQ; routine process residue monitoring may be reduced based on validated aeration parameters and residue testing history.

**ISO 11135 (EtO):** EtO residue assessment under ISO 10993-7:2008 is more complex and more consequential than VHP. EtO reacts with the product and packaging to form two reaction products: ethylene chlorohydrin (ECH, when chlorine is present) and ethylene glycol (EG). Both are regulated. ISO 10993-7 establishes maximum allowable limits for EtO, ECH, and EG per device category. Aeration time and temperature are set to achieve residue below these limits, and residue testing is required. EtO residue assessment is a primary regulatory concern — FDA warning letters have cited inadequate EtO residue testing as a finding — and it represents a significant component of the EtO validation documentation burden that VHP does not carry.

**ISO 11137 (Radiation):** Radiation sterilization does not produce chemical residues in the same sense. Gamma and E-beam irradiation can induce radiolytic effects in device materials — degradation of polymers, changes in material properties — but these are addressed through material compatibility assessment rather than residue testing per se. ISO 11137 requires assessment of radiation effects on product materials as part of process development, but there is no equivalent to the EtO or VHP residue testing requirement.

Routine Process Monitoring and Requalification

All three standards require ongoing process monitoring after initial validation to confirm that the sterilization process remains in its validated state.

**ISO 22441 (VHP):** Routine monitoring includes parametric release (cycle parameter records confirming H₂O₂ concentration, temperature, humidity, dwell time, and aeration within the validated range), periodic BI challenge runs at the frequency specified in the validation program, and annual or periodic process review against the original qualification data. Changes to the chamber, load configuration, or cycle parameters that exceed the validated range require requalification within the scope of the change.

**ISO 11135 (EtO):** Routine monitoring parallels VHP in structure: parametric release from cycle records (gas concentration, temperature, humidity, exposure time, aeration), periodic BI challenge runs, and periodic residue testing. EtO has an additional monitoring obligation — occupational exposure monitoring for workers in sterilization areas, per OSHA EtO standards — that has no equivalent in VHP operations.

**ISO 11137 (Radiation):** Routine monitoring for radiation uses dosimetry rather than BIs. Routine dosimeters are placed at the minimum-dose location in the irradiation container for each production batch, and the measured dose is confirmed to meet or exceed the established minimum dose before product release. Periodic dose audits (quarterly dosimetry runs at multiple positions) confirm that the dose distribution has not changed from the validated configuration. Requalification is triggered by changes to the irradiator geometry, the irradiation container configuration, or product density changes beyond the validated range.

Documentation Architecture

The documentation deliverables of all three validation programs are organized around the same structure: validation plan, IQ report, OQ report, PQ report, validation master record, and ongoing monitoring records. The content is method-specific; the architecture is identical.

This equivalence is directly practical: a device manufacturer with an existing EtO validation master record, IQ/OQ/PQ report structure, and change control system has the documentation architecture required for an ISO 22441 VHP validation program. The forms, templates, review cycles, and approval logic do not need to be rebuilt. The content changes to reflect VHP-specific parameters; the structure does not.

For manufacturers who have submitted EtO or radiation sterilization validation data in FDA 510(k) submissions, the sterility section of a VHP submission follows the same organizational logic. FDA's guidance on sterilization for 510(k)s references the applicable standard (ISO 22441) in the same way it references ISO 11135 or ISO 11137 for other methods. The submission format is equivalent; the standard cited changes.

The Single Remaining Difference: Process Ownership

The comparison above identifies a structural equivalence across all three frameworks in biological indicator logic, validation lifecycle architecture, documentation structure, and residue assessment requirements. The one genuine operational difference — beyond the method-specific parameters — is process ownership.

EtO sterilization, for the majority of device manufacturers, is performed by a contract sterilizer. The validation is joint: the device manufacturer develops the product load configuration and validates the cycle on the contract sterilizer's equipment, to the contract sterilizer's process specification. The process is run by the contract sterilizer's operators, on the contract sterilizer's equipment, in the contract sterilizer's facility. The device manufacturer is dependent on that external organization for product release.

Radiation sterilization is almost universally performed by contract irradiation facilities. The device manufacturer has no realistic in-house alternative — gamma irradiators and E-beam accelerators are capital infrastructure that device manufacturers do not own. Process ownership is fully external.

VHP sterilization is designed for in-house operation. PuroGen's [SteriFlex platform](/steriflex) is an in-house system: the device manufacturer owns the equipment, operates the validated cycle, and controls the process. The sterilization step — which governs every downstream product release activity — is an internal operation, not an external dependency. The [capabilities and validation heritage](/capabilities) that support ISO 22441-compliant process development are available to manufacturers who are moving this step in-house for the first time.

For teams evaluating VHP as a transition from EtO or radiation, the technical comparison in this article confirms that the validation knowledge they have already built is directly applicable. The method is different. The framework is the same. The process, for the first time, can be owned.

Frequently Asked Questions

**Is the biological indicator organism for VHP the same as for EtO?**

No. ISO 22441 specifies *Geobacillus stearothermophilus* for VHP — the same organism used for steam sterilization validation, chosen for its resistance to oxidizing agents. ISO 11135 specifies *Bacillus atrophaeus* (ATCC 9372) for EtO, chosen for its resistance to alkylating agents. The organisms reflect the different kill mechanisms: VHP achieves sporicidal kill through oxidation; EtO achieves it through alkylation of nucleic acids and proteins. ISO 11137 uses *Bacillus pumilus* ATCC 27142 in dose-setting studies for gamma and E-beam. Validation teams transitioning from EtO to VHP must change their BI supplier and organism, update their BI qualification documentation, and verify that incubation protocols reflect *G. stearothermophilus* requirements (typically 55–60°C incubation, 7 days, growth/no-growth or quantitative readout).

**Do I need to redo IQ/OQ/PQ if I already have a validated EtO process?**

Yes — but the existing EtO validation documentation is directly useful as a structural model. An existing IQ/OQ/PQ report structure, change control system, and validation master record architecture are applicable to the VHP program without redesign. The content of each qualification phase must be executed for the VHP system specifically — the IQ documents the VHP generator and chamber, the OQ maps VHP parameters in the specific chamber, and the PQ demonstrates sporicidal efficacy with *G. stearothermophilus* BIs at worst-case locations in the specific load configuration. The prior EtO validation does not transfer its technical conclusions to VHP, but it provides the documentation architecture and the validation team's expertise with the IQ/OQ/PQ lifecycle.

**How does dose-setting under ISO 11137-2 compare to cycle development under ISO 22441?**

They are fundamentally different in structure. ISO 11137-2 dose-setting (Method 1, Method 2, or VDmax) derives the sterilization dose from product bioburden data — the required dose is calculated from the measured bioburden distribution and the SAL target, then confirmed by a verification dose experiment. The device manufacturer submits bioburden samples; the irradiation facility delivers the calculated dose; the verification experiment confirms the dose-bioburden relationship. ISO 22441 cycle development requires the manufacturer's validation team to develop, optimize, and qualify a parametric cycle — H₂O₂ concentration, temperature, humidity, dwell time — on a specific chamber with a specific load configuration, demonstrated by BI challenge at worst-case locations. The ISO 22441 process requires more active internal development effort; the ISO 11137-2 approach relies more heavily on bioburden data and the irradiation facility's expertise. For teams moving from radiation to VHP, this is the largest operational shift in the validation approach.

**Is residue testing more burdensome for VHP than for EtO?**

No — significantly less burdensome. EtO residue assessment under ISO 10993-7 requires testing for EtO, ethylene chlorohydrin, and ethylene glycol against defined limits that vary by device category (implant, external communicating, external devices). The testing is analytical chemistry with method development requirements, and the results are a primary regulatory concern. VHP residue assessment under ISO 21396 measures hydrogen peroxide residuals; after a fully aerated cycle, H₂O₂ decomposes to water and oxygen, and residue levels are typically well below biocompatibility limits established under ISO 10993-17. The VHP residue testing burden is lower in analytical complexity and lower in regulatory consequence than EtO. It is a required documentation element, not a primary compliance risk.

**Can the same validation team that executes EtO validations execute VHP validations under ISO 22441?**

Yes, with appropriate training and equipment familiarization. The structural knowledge — IQ/OQ/PQ lifecycle, BI qualification, process challenge studies, documentation architecture, regulatory submission formats — is directly transferable. Method-specific training is required on VHP cycle physics (the four-phase cycle, condensation dynamics, parametric relationships), the *G. stearothermophilus* BI and its VHP-specific D-values, the VHP generator and chamber instrumentation, and ISO 22441's specific requirements for cycle development and residue assessment. Contract validation laboratories including Nelson Labs, SGS, and Charles River Laboratories offer ISO 22441 validation support services and can supplement internal teams during the first program execution.

**Where does PuroGen fit in the VHP validation ecosystem?**

PuroGen develops and validates VHP sterilization platforms — the [SteriFlex system](/steriflex) is the core technology for device and pharmaceutical applications. The [science and validation documentation](/science) reflects decades of process development across allograft tissue, medical devices, and pharmaceutical environments. PuroGen's commercial pathways include direct deployment of validated platforms and [strategic collaboration](/strategic) for partners building in-house VHP capability. For manufacturers evaluating the transition from EtO or radiation to VHP and wanting to understand how ISO 22441 applies to their specific product and regulatory context, the [capabilities page](/capabilities) and [contact](/contact) are the appropriate starting points. The existing [VHP validation pathway article](/insights/vhp-validation-pathway-iso-22441-category-a) provides additional context on the FDA submission framework that ISO 22441 supports.